Analysts have reset their price target on Emergent BioSolutions to US$12 from US$15, keeping the fair value estimate at US$12 ...

Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV ...

The average one-year price target for Emergent BioSolutions (NYSE:EBS) has been revised to $12.24 / share. This is a decrease ...

Emergent BioSolutions was awarded a contract worth about $54 million to supply the Administration for Strategic Preparedness and Response with additional doses of Vigiv, a treatment for smallpox ...

Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® ...

Artis BioSolutions Establishes U.S.-based Synthetic DNA Manufacturing Hub in Boston Share Expanded facility integrates Syngoi Technologies’ enzymatic DNA platform into Artis’ North American operations ...

Emergent BioSolutions Inc. (NYSE:EBS) shares rose 4.5% in after-hours trading Wednesday following the announcement of a $54 million contract with the Administrati ...

Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with Dyadic ...

Artis was founded to provide platforms and capabilities that drug developers require to bring next-generation medicines to patients.